ClinicalTrials.Veeva

Menu

Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid Arthritis

Eisai logo

Eisai

Status

Completed

Conditions

Rheumatoid Arthritis

Treatments

Drug: Iguratimod

Study type

Observational

Funder types

Industry

Identifiers

Details and patient eligibility

About

To investigate the safety and efficacy of the administration of Iguratimod (CRM01T) for 52 weeks in patients with rheumatoid arthritis in clinical practice

Enrollment

2,747 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria

  • Participants with rheumatoid arthritis
  • Participants who take iguratimod

Exclusion criteria

  • Participants registered for this survey previously
  • Pregnant women or women suspected of being pregnant
  • Participants with a serious liver disorder
  • Participants with peptic ulcer
  • Participants with known hypersensitivity to iguratimod or any of its excipients

Trial design

2,747 participants in 1 patient group

Iguratimod
Treatment:
Drug: Iguratimod

Trial contacts and locations

453

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems